SaaS+AI，藥師幫(09885.HK)或正解鎖醫藥下沉市場變革新密碼
近期，"AI+醫藥"板塊表現亮眼，成爲市場關注的焦點。隨着AI技術在智能診療、精準營銷及健康管理等方面的廣泛應用，醫藥行業正加速邁向智能化升級。在此背景下，互聯網醫藥平臺憑藉其廣泛的市場覆蓋和數據積累，有望成爲AI技術落地的重要場景。"醫藥拼多多"藥師幫早以"平臺+SaaS服務"爲切入點
並深度佈局，在這場技術引領的行業變革競賽中似乎已佔據先發優勢，或將進一步獲資本市場追捧。
在醫藥行業版圖中，院外市場以其獨特的格局佔據重要地位。據統計，全國零售藥房數量超 60 萬家，診所及衛生室更是數以百萬計。弗洛斯特沙利文數據顯示，院外市場預計 2027 年將突破萬億元大關。這片萬億級藍海市場中，不僅蘊藏着廣闊的市場需求，也潛藏着巨大的技術革新潛力。
目前，藥師幫的SaaS產品矩陣——雲商通、掌店易、光譜雲診，包括旗下一塊醫藥的PHDS藥房健康診斷系統已覆蓋醫藥產業鏈的多個核心環節，在助力藥企打造智能供應鏈、賦能藥店數字化升級，提升基層智慧醫療服務等方面均有深度佈局。值得一提的是，區別於市場上的概念選手，其SaaS產品矩陣已在院外下沉市場取得可觀的商業化成果，隨着用戶規模的持續擴大，訂閱費、服務費等多種模式下的商業化收入同樣表現出強勁的增長潛力。
近日，藥師幫也宣佈正接入DeepSeek等前沿大模型，致力於推動AI技術在院外基層醫藥市場的廣泛普及與深度應用。AI技術的發展離不開海量數據的支撐，數據如同AI的"燃料"，而藥師幫在這方面擁有得天獨厚的優勢。公開信息顯示，其已服務的藥店診所數已超74萬家。憑藉廣泛覆蓋的下沉市場銷售渠道和SaaS產品矩陣，藥師幫已然成爲院外醫藥領域最大的數據入口。這些海量數據資源涵蓋了藥品流通、市場需求、用戶行爲、診療記錄等多個維度，爲人工智能和技術的運用提供了廣闊的應用場景和數據基礎。
可以預見，先進的AI能力與藥師幫SaaS產品矩陣的深度融合，將加速AI技術在院外醫藥產業鏈垂的應用與成長，推動其潛在價值的全面釋放。通過AI技術的賦能，藥師幫可以深度挖掘海量數據的商業價值，將進一步優化供應鏈管理、提升藥店運營效率、推動智慧醫療服務，改善用戶體驗，或將爲院外醫藥市場帶來革命性的數智化變革。在DeepSeek等前沿技術的加持下，也有望釋放更大的乘數效應，其市場潛力不容小覷。
此外，多家券商發佈研究報告指出，"AI+醫藥"板塊具有長期的增長潛力，預計該板塊將迎來更加廣闊的發展空間和市場前景，資本市場對"AI+醫藥"該板塊的關注度持續提升。院外醫藥數字化市場空間巨大，尤其是在下沉市場，數字化和AI技術的應用潛力尚未完全釋放。隨着政策支持、技術進步和市場需求的推動，這一領域將迎來爆發式增長。而藥師幫手握龐大的用戶基礎和海量的客戶資源，或許正是其留給資本市場最大的想象空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
